2026 International Congress of Diabetes and Metabolism(3일차)

세부 일정 (75강)

• 08:00~08:15 Phenomapping-driven antiplatelet therapy for primary prevention in diabetic patients: who gets what? Room 4 윤재승(가톨릭의대 내과)
• 08:00~08:15 The necessity of SGLT2i in the management of CKM syndrome Room 5 류영상(조선의대 내과)
• 08:00~08:15 Beyond statins: a new era of oral lipid-lowering therapy for statin-intolerant patients Room 6 홍준화(을지의대 내과)
• 08:15~08:30 The clinical importance of sulfonylurea and SGLT2 inhibitor in the management of type 2 diabetes Room 4 양여리(가톨릭의대 내과)
• 08:15~08:30 TZD+SGLT-2i combination therapy: benefits for diabetic complications and MASLD Room 5 노은(서울의대 내과)
• 08:15~08:30 Fenofibrate in cardiometabolic health: clinical utility and safety in dyslipidemia management Room 6 Richard O(University of Melbourne)
• 08:30~09:00 휴식 ( )
• 09:00~09:25 From cardiometabolic evidence to individualized CKM care Room 1 Per-Henrik Groop(University of Helsinki Finland)
• 09:25~09:50 Recognizing high-risk CKM phenotypes beyond HbA1c Room 1 Yu Mi Kang(Harvard University USA)
• 09:50~10:15 Synergistic use of cardiometabolic therapies across CKM stages Room 1 Hiddo Lambers Heerspink(University Medical Center Groningen)
• 09:00~09:25 Oral non‑peptide GLP-1 receptor agonists: mechanisms and therapeutic potential in metabolic disease Room 2 Luc Van Gaal(Antwerp University)
• 09:25~09:50 Achieve program: translating phase 3 evidence into clinical practice in type 2 diabetes Room 2 조영민(서울의대 내과)
• 09:50~10:15 Attain and beyond: clinical implications of phase 3 obesity trials in cardiometabolic care Room 2 이승환(가톨릭의대 내과)
• 09:00~09:20 Tissue engineering, biocompatible hydrogel, multifunctional nanoparticles, surface modified substrate Room 3 황석연(서울대학교 화학생물공학부)
• 09:20~09:40 Immune-evasive human islet-like organoids ameliorate diabetes Room 3 Eiji Yoshihara(UCLA USA)
• 09:40~10:00 Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient Room 3 Shusen Wang(Nankai University China)
• 10:00~10:20 Panel discussion Room 3 이은영 이기현 김형석(가톨릭의대 내과 이화여대 약학대학 충남의대 생화학교실)
• 09:00~09:20 Characteristics of beta-cell dysfunction in Korean T2D Room 4 김남훈(고려의대 내과)
• 09:20~09:40 Glucocentric view of beta-cell preservation Room 4 원규장(영남의대 내과)
• 09:40~10:00 Toward β-cell recovery in diabetes: quantitative imaging and stress-adaptive β-cell remodeling Room 4 Takaaki Murakami(Kyoto University Japan)
• 10:00~10:20 Panel discussion Room 4 이준엽 전재한 문준호(가톨릭의대 내과 경북의대 내과 서울의대 내과)
• 09:00~09:25 Evolving treatment strategies in diabetic kidney disease: from RAAS blockade to MRA and GLP-1 RAs Room 5 김미경(계명의대 내과)
• 09:25~09:50 Current and emerging treatments for MASLD: an update Room 5 한유진(계명의대 내과)
• 09:50~10:15 Achieving and maintaining weight loss in patients with diabetes Room 5 김보연(순천향의대 내과)
• 10:15~10:30 휴식 ( )
• 10:30~11:10 Evidence-based and updated CKM preventive strategies, clinical trials Room 1 Darren McGuire(University of Texas Southwestern Medical Center USA)
• 11:10~11:50 MASLD: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment Room 1 Norbert Stefan(University Tübingen Germany)
• 11:50~12:05 Transforming the trajectory of T2D treatment thorugh Early intensive invervention with GIP/GLP-1 Dual agonist Room 2 Luc Van Gaal(Antwerp University)
• 11:50~12:05 IcoSema: redefining injectable therapy for type 2 diabetes Room 3 Ryo Suzuki(Tokyo Medical University)
• 11:50~12:05 A new era of CKD and T2D management: a holistic approach with nsMRA Room 4 서다혜(인하의대 내과)
• 11:50~12:05 Advances in diabetes management clinical benefits of SGLT-2 inhibitors in combination therapy Room 5 최종한(건국의대 내과)
• 12:05~12:20 Rethinking diabetes care: why kidney protection can no longer wait Room 2 Per-Henrik Groop(University of Helsinki)
• 12:05~12:20 The Importance of preventing shingles in diabetic patients and the role of endocrinologist Room 3 박정환(한양의대 내과)
• 12:05~12:20 The optimal combination therapy with TZD and SGLT2i Room 4 정창희(울산의대 내과)
• 12:05~12:20 Exploring clinical data for hypertensive patients with kidney disease Room 5 정경혜(충남의대 내과)
• 12:20~13:20 점심식사 ( )
• 13:20~13:40 Lactation-driven metabolic reprogramming of adipose tissue Room 1 문준호(서울의대 내과)
• 13:40~14:00 CGM-derived glycemic trajectories reflect β-cell decline across dysglycemia Room 1 이준엽(가톨릭의대 내과)
• 14:00~14:20 Hidden in plain sight: redefining risk through lipids, adiposity, and pregnancy in metabolic disease Room 1 정한나(한림의대 내과)
• 14:20~14:40 Sympathetic circuit heterogeneity in multi-organ metabolic regulation Room 1 주상현(KAIST)
• 13:20~13:45 Modern treatment of CKD in diabetes Room 2 Per-Henrik Groop(University of Helsinki)
• 13:45~14:10 Anchoring early CKM care: EMPA FIT vs metformin in treatment-naïve T2D Room 2 임수(서울의대 내과)
• 14:10~14:35 Expanding CKM to liver health with GLP-1/GCGR dual agonist (phase 3 updates) Room 2 홍준화(을지의대 내과)
• 13:20~13:45 Aging, kidney health, and diabetes: epidemiologic implications for healthy longevity Room 3 Shigeo Horie(Juntendo University Japan)
• 13:45~14:10 Towards validating the unitary hypothesis: are fundamental aging mechanisms in adipose depots concentrated within tissue crown-like structures? Room 3 James L. Kirkland(Cedars-Sinai Medical Center USA)
• 14:10~14:35 Senotherapeutics: translating research into clinical reality Room 3 전옥희(고려의대)
• 13:20~13:40 Taming the 'invisible' rice spike: why reliable PPG control matters in resource-limited settings Room 4 Olive De Guzman-Quizon(Manila Doctors Hospital)
• 13:40~14:00 Fighting obesity in Asia: beyond weight loss, gaining health Room 4 Chan Siew Pheng(Subang Jaya Medical Centre)
• 14:00~14:20 Protecting the vulnerable: safety strategies for older adults & CKD patients Room 4 Navaporn Napartivaumnuay(Rajvithi Hospital)
• 14:20~14:40 Time is pancreas: why Korea prioritizes early combination therapy Room 4 김소헌(인하의대 내과)
• 13:20~13:45 Differentiating type 1 and type 2 diabetes: diagnostic challenges and treatment strategies Room 5 진상만(성균관의대 내과)
• 13:45~14:10 Key educational points for insulin pump therapy Room 5 이수지(강북삼성병원)
• 14:10~14:35 Optimizing resistance exercise in patients with diabetes on injectable therapies Room 5 정승재(삼성서울병원)
• 13:20~13:45 The one ring of diabetology, everything about insulin Room 6 문준성(영남의대 내과)
• 13:45~14:10 How CGM has transformed diabetes care Room 6 김재현(성균관의대 내과)
• 14:10~14:35 Landmark studies that changed the paradigm of diabetes treatment Room 6 김신곤(고려의대 내과)
• 14:35~14:50 휴식 ( )
• 14:50~15:15 Expanding the evidence of diabetes technology in special populations: older adults to pregnancy Room 1 유지희(중앙의대 내과)
• 15:15~15:40 Beyond prevention: CGM as a tool for treatment optimization in pre-type 2 diabetes Room 1 Rimei Nishimura(Jikei University Japan)
• 15:40~16:05 Current status and future perspectives of fully closed-loop systems for type 2 diabetes in Korea Room 1 문선준(성균관의대 내과)
• 14:50~15:15 Managing hyperkalemia in diabetes Room 2 Hideki Yokoi(Kumamoto University Japan)
• 15:15~15:40 Managing uncontrolled hypertension in diabetes Room 2 이해영(서울대학교병원)
• 15:40~16:05 Managing obesity in diabetes Room 2 유성훈(한양의대 내과)
• 14:50~15:15 Reappraising pioglitazone: metabolic modification and organ protection Room 3 Kenneth Cusi(University of Florida)
• 15:15~15:40 Re-evaluating macrovascular outcomes and practical management method of pioglitazone Room 3 홍준화(을지의대 내과)
• 15:40~16:05 Complementary combination strategies: positioning pioglitazone in the era of modern agents Room 3 김규리(성균관의대 내과)
• 14:50~15:10 Characteristics of diabetes in East Asia with a focus on nonobese phenotype Room 4 Yuji Yamazaki(Kansai Electric Power Medical Research Institute)
• 15:10~15:30 Lean diabetes in South Asians: what exactly is it? Room 4 Viswanathan Mohan(Madras Diabetes Research Foundation)
• 15:30~15:45 Secondary causes of diabetes Room 4 Lee-Ling Lim(Universiti Malaya)
• 15:45~16:00 Lean diabetes: 20-year trends in its prevalence and clinical features among Korean adults Room 4 이주희(충남의대 내과)
• 16:00~16:10 Panel discussion Room 4 김혜진 허지혜(아주의대 내과 한림의대 내과)
• 14:50~15:10 Nicotinamide riboside attenuates ritonavir-induced lipodystrophy and systemic side effects Room 5 Yan Zhang(Central Hospital of Dalian University of Technology China)
• 15:10~15:30 Targeting carbonic anhydrase 3 enhances skeletal muscle regeneration via a non-canonical AKT-GSK3β-PGC1α pathway to rejuvenate aged satellite cells Room 5 Darren R. Williams(GIST)
• 15:30~15:50 Mitochondrial metabolic reprogramming to combat sarcopenia Room 5 강종순(성균관대학교 의과대학)
• 15:50~16:10 Panel discussion Room 5 서재명 오창명 전재한(카이스트 GIST 경북의대 내과)